CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic research collaboration with Bristol Myers Squibb (NYSE: BMY). The two companies will work together to identify new targets and validate them faster and with higher confidence using multimodal datasets, computational approaches, and patient-derived disease models in specific cancer disease areas..

芝加哥-（商业时报）-人工智能和精准医学领导者Tempus今天宣布与Bristol-Myers Squibb（纽约证券交易所：BMY）进行为期多年的战略研究合作。这两家公司将共同努力，使用多模式数据集，计算方法和特定癌症疾病领域的患者衍生疾病模型，更快，更有信心地确定新目标并对其进行验证。。

'We are looking forward to expanding our relationship with Bristol Myers Squibb and furthering our shared commitment to advancing cancer research and treatment options for patients that need it most,” said Ryan Fukushima, Chief Operating Officer at Tempus. “By combining the power of Tempus’ multimodal data, biological modeling, and machine learning approaches with Bristol Myers Squibb’s discovery expertise and research and development capabilities, we can accelerate discoveries, innovate therapies, and improve the lives of patients battling cancer.”.

Tempus首席运营官瑞安福岛（Ryan Fukushima）说：“我们期待扩大与百时美施贵宝（Bristol-Myers Squibb）的关系，并进一步致力于推进最需要它的患者的癌症研究和治疗方案。“通过将Tempus的多模式数据，生物建模和机器学习方法的力量与百时美施贵宝的发现专业知识和研究开发能力相结合，我们可以加速发现，创新疗法，改善与癌症作斗争的患者的生活。”。

The Tempus and Bristol Myers Squibb teams will focus their initial research on identifying new drug targets to expand options for patients lacking effective therapies, or who have become refractory to existing treatment. Teams from both companies will work in a highly collaborative manner to jointly analyze disease cohorts within Tempus’ large multimodal database and apply systems biology approaches to uncover novel targets that can be quickly and iteratively tested using Tempus’ library of patient-derived organoids..

Tempus和Bristol-Myers Squibb团队将重点研究确定新的药物靶点，以扩大缺乏有效治疗或对现有治疗无效的患者的选择。两家公司的团队将以高度协作的方式共同分析Tempus大型多模式数据库中的疾病队列，并应用系统生物学方法揭示新的目标，这些目标可以使用Tempus“患者衍生类器官库”快速迭代测试。。

About Tempus

关于Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Tempus是一家通过人工智能在医疗保健领域的实际应用推进精准医学的技术公司。凭借世界上最大的多模式数据库之一，以及使数据可访问和有用的操作系统，Tempus为医生提供支持AI的精准医学解决方案，以提供个性化的患者护理，同时促进最佳治疗方法的发现，开发和交付。

The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com..

目标是让每位患者通过向医生提供在公司收集更多数据时学习的工具，从之前的其他患者的治疗中受益。欲了解更多信息，请访问tempus.com。。